Rheumatoid Arthritis Management

Introduction to Rheumatoid Arthritis

Rheumatoid arthritis (RA) management aims to achieve remission or low disease activity, preventing joint damage and disability, as recommended by the European League Against Rheumatism 1
Early referral to a rheumatologist, ideally within 6 weeks of symptom onset, is crucial for optimal management, as recommended by the European League Against Rheumatism 2

Methotrexate (MTX) is recommended as the first-line disease-modifying antirheumatic drug (DMARD), with an initial dose of 15 mg/week and folic acid 1 mg/day, to be started as early as possible, ideally within 3 months of symptom onset, as recommended by the American College of Rheumatology 3, 4, 5, 6, 7, 8
The European League Against Rheumatism recommends initiating or adjusting disease-modifying antirheumatic drugs (DMARDs) for long-term control, considering methotrexate as the anchor drug for long-term management 4
The American College of Rheumatology recommends adding hydroxychloroquine and sulfasalazine to MTX (triple therapy) for patients with rheumatoid arthritis 5
Hydroxychloroquine is considered the safest DMARD in cirrhosis, with a standard dose of 200-400 mg daily and minimal hepatic metabolism, requiring regular ophthalmologic monitoring, as recommended by the European League Against Rheumatism 3
Sulfasalazine is generally safe in stable cirrhosis, with a starting dose of 500 mg daily and gradual increase to 2-3 g/day, requiring monitoring of liver function tests every 1-3 months initially, as recommended by the American College of Rheumatology 3

Adding a biologic DMARD to MTX is also recommended, with options including TNF inhibitors, IL-6 receptor antagonists, T-cell co-stimulation modulators, and anti-CD20 monoclonal antibodies 3
Switching to an alternative biologic with a different mechanism of action is recommended for patients who do not respond to initial biologic therapy 5, 9
The American College of Rheumatology recommends considering tocilizumab or abatacept in patients who are seronegative for rheumatoid factor after inadequate response to TNF inhibitors 5
TNF inhibitors can be safely administered in patients with cirrhosis, especially with concomitant antiviral therapy for hepatitis C, with etanercept possibly having a better hepatic safety profile than other TNF inhibitors, as recommended by the American College of Rheumatology 3
IL-6 inhibitors, such as tocilizumab, may be considered in patients with stable cirrhosis, with less hepatotoxicity than conventional DMARDs, requiring regular monitoring of liver function tests, as recommended by the European League Against Rheumatism 3
Abatacept, a T-cell co-stimulation modulator with minimal hepatic metabolism, can be considered in patients with stable cirrhosis, as recommended by the American College of Rheumatology 3

Screening for tuberculosis is recommended before starting biologic therapy, according to the American College of Rheumatology 3, 9
Regular monitoring of disease activity using composite measures is essential, according to the American College of Rheumatology 4
The following thresholds for disease activity assessment are recommended by EULAR:
State DAS28 CDAI SDAI
Remission <2.6 ≤2.8 ≤3.3
Low activity 2.6-3.2 >2.8-10 >3.3-11
Moderate activity 3.2-5.1 >10-22 >11-26
High activity >5.1 >22 >26 [10]
Disease activity should be assessed every 1-3 months using composite measures, and the target should be remission or low disease activity within 6 months, as recommended by the European League Against Rheumatism 1, 4

State	DAS28	CDAI	SDAI
Remission	<2.6	≤2.8	≤3.3
Low activity	2.6-3.2	>2.8-10	>3.3-11
Moderate activity	3.2-5.1	>10-22	>11-26
High activity	>5.1	>22	>26	[10]

The European League Against Rheumatism recommends treating acute RA flares with colchicine (within 12 hours of flare onset) at a loading dose of 1 mg followed 1 hour later by 0.5 mg on day 1, and/or an NSAID (with a proton pump inhibitor if appropriate), or oral corticosteroids (30-35 mg/day of equivalent prednisolone for 3-5 days) 11
Oral corticosteroids, such as prednisolone (35 mg/day for 5 days), have been shown to be equivalent to naproxen (500 mg twice daily for 5 days) for treating flares, according to the European League Against Rheumatism 11
Intra-articular corticosteroid injection is particularly effective for monoarticular flares, providing rapid local relief of inflammation, according to the European League Against Rheumatism 11

Dynamic exercises and occupational therapy can be used as adjuncts to drug treatment, and smoking cessation, dental care, weight control, and assessment of vaccination status are also important, as recommended by the European League Against Rheumatism 4
Patient education about the disease, its outcomes, and treatment options is crucial, according to the European League Against Rheumatism 4
Occupational therapy and assistive devices can help protect joints and improve function, according to the European League Against Rheumatism 5
Dynamic exercise programs that incorporate aerobic exercise and strength training can improve symptoms and function, as recommended by the European League Against Rheumatism 5
Patient education on disease management and self-care skills is essential, including weight loss, regular exercise, and smoking cessation, as recommended by the European League Against Rheumatism 5

Consider tapering medication only after sustained low disease activity or remission for at least 6 months, as recommended by the American College of Rheumatology 6 and EULAR 1
Taper in this order: first glucocorticoids, then biologics, then conventional DMARDs, according to EULAR guidelines 1
Reduce doses gradually rather than abrupt discontinuation, as recommended by EULAR 1 and the American College of Rheumatology 6

Surgical options such as arthroscopy, osteotomy, and arthroplasty may be considered for patients with significant functional limitation and failed conservative treatment, as recommended by the European League Against Rheumatism 3